- Home
- MIRM
as 11-15-2024 4:00pm EST
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 1.9B | IPO Year: | 2019 |
| Target Price: | $57.00 | AVG Volume (30 days): | 340.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.14 - $48.89 | Next Earning Date: | 11-12-2024 |
| Revenue: | $307,028,000 | Revenue Growth: | 112.14% |
| Revenue Growth (this year): | 73.07% | Revenue Growth (next year): | 27.98% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heron Patrick J | MIRM | Director | Sep 18 '24 | Buy | $37.40 | 115 | $4,301.00 | 162,308 | |
| Heron Patrick J | MIRM | Director | Sep 6 '24 | Buy | $41.58 | 230 | $9,563.01 | 162,308 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
Simply Wall St.
18 hours ago
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
Business Wire
2 days ago
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
Simply Wall St.
2 days ago
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
3 days ago
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...
Zacks
4 days ago
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
Zacks
4 days ago
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
MT Newswires
4 days ago
Mirum Pharmaceuticals' Q3 Loss Narrows, Revenue Rises
Business Wire
4 days ago
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.